The shares of Aurobindo Pharma will be in focus in today's session as the USFDA issued a Form 483 with a total of nine ...

Eugia III resolution (in the backdrop of fresh observations) and the launch momentum across geographies would be key determinants, say analysts.

Aurobindo Pharma Ltd (BOM:524804) reports robust revenue growth driven by European operations and US injectable sales, while addressing regulatory challenges and strategic acquisitions.

Aurobindo Pharma posted a 7.5% year-on-year rise in Q3 FY26 net profit to ₹909.8 crore despite a one-time labour code cost, ...

At previous close, the Sensex was up 485.35 points (0.58 percent) at 84,065.75, and the Nifty was up 173.60 points (0.68 percent) at 25,867.3 Shares of Aurobindo Pharma declined 6.46% to Rs 1,125.90, ...

Financial data reveals mixed quarterly performance but generally positive annual trends for Aurobindo Pharma, KPR Mill, PB Fintech, and Hind Zinc.

This article first appeared on GuruFocus. Aurobindo Pharma Ltd (NSE:AUROPHARMA) is set to release its Q3 2026 earnings on Feb 10, 2026. The consensus estimate for Q3 2026 revenue is $83.16 billion, ...

Feb 9 (Reuters) - Indian drugmaker Aurobindo Pharma reported a 7.6% rise in profit on Monday, helped by steady domestic demand, especially for its anti-retroviral drugs for HIV infections.

Aurobindo Pharma posted an 8% increase in Q3 net profit to ₹910 crore, aided by steady sales performance and improved ...

Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to Rs 910 crore for the December quarter, led by robust sales in Europe and the US.

The brokerage noted that Aurobindo is expected to complete the Rs 2,075 crore acquisition of Lannett in Q1 FY27, which may add nearly 7% to FY27 US revenue growth.

Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to Rs 910 crore for the ...